Status:
COMPLETED
A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Urinary Bladder, Overactive
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid
Eligibility Criteria
Inclusion
- Patients willing and able to complete the micturition diary correctly
- Patients experiencing frequency of micturition as verified in the diary
- Patients experiencing significant post void residual volume
- OAB symptoms including urinary frequency, urgency or urge incontinence for 3 months or more.
Exclusion
- Significant post void residual volume
- Patients with indwelling catheters or practicing intermittent self- catheterization
- Known or suspected hypersensitivity to solifenacin succinate or other anticholinergics or lactose
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
246 Patients enrolled
Trial Details
Trial ID
NCT00368706
Start Date
September 1 2006
End Date
March 1 2008
Last Update
April 10 2008
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing, China, 100000
2
Chongqing, China, 404000
3
Hangzhou, China, 310000
4
Shanghai, China, 200000